HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Add as a preferred source on Google
NEW YORK, April 23, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities between September 12, 2016 and February 27, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/celgene-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the trials for GED-0301 suffered from fatal design defects, such that GED-0301 had failed to demonstrate meaningful clinical efficacy; (3) the growth of Otezla sales had dramatically slowed during Celgene's third fiscal quarter of 2017; and (4) the clinical and nonclinical pharmacology data in Celgene's new drug application ("NDA") for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
If you suffered a loss in Celgene you have until May 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/celgene-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
